I-Pap smear ingasiza ekwehliseni izinga lomdlavuza womlomo wesibeletho. Ucwaningo olusha luveza ukuthi zingasetshenziswa futhi ukuhlonza eminye imidlavuza yabesifazane kusenesikhathi. Ithishu noketshezi oluqoqwe ngesikhathi se-Pap smear kungatholwa ngofuzo ukuze kutholwe umdlavuza we-endometrial nowe-ovary. Umcwaningi uDkt. Amanda Fader uthe uma kutholakala umdlavuza, kungasindiswa imiphefumulo yezinkulungwane unyaka nonyaka ngokubamba le midlavuza kusesigabeni sokuqala neselaphekayo.
The main goal is to be able to detect these cancers through mutations in isisu genes, which are usually found in the blood or fluids collected from the cervix and vagina. Uma singawuthola umdlavuza kusenesikhathi noma ekuqaleni komdlavuza, akunakwenzeka kuphela ukuthi uthole ukwelashwa okwengeziwe, kodwa futhi kuzovikela nabesifazane abaningi ekutholeni inzalo ethe xaxa.
Ku-Pap smear, udokotela usebenzisa i-spatula noma ibhulashi ukuqoqa amaseli emlonyeni wesibeletho, athunyelwe elabhorethri ayohlaziywa.
The researchers developed a test protocol called PapSEEK to see if other samples collected during the pelvic exam can be used to detect endometrial cancer or isibeletho umdlavuza. I-PapSEEK ingathola ukuguqulwa kwe-DNA okukhonjwe njengomdlavuza othile, kufaka phakathi izakhi zofuzo ezi-18 ezivame ukushintshwa.
Ukubona ukuthi ukuhlolwa kuyasebenza yini, abacwaningi baqoqa amasampula kwabesifazane abangu-1,658, abangu-656 kubo babenomdlavuza we-endometrial noma i-ovarian, kanye nabesifazane abangu-1,000 XNUMX abaphilile njengeqembu lokulawula. Ucwaningo lukhombisile ukuthi ukuhlolwa kwePapSEEK kungathola ngokunembile ama-81% omdlavuza we-endometrial kanye nama-33% womdlavuza we-ovari. Lapho abacwaningi besebenzisa amabhulashi ukuqoqa amasampula, ukutholwa okunembile kukhuphuke kwaba ngu-93% no-45%, ngokulandelana.
Lona umphumela wokuqala wokuqala futhi ubukeka uthembisa, kepha kusese nendlela ende okufanele uhambe ngayo ukuthola ukuthi ngabe lokhu kuwusizo ngempela yini.
